Highlights
- Tandem shares gained 14.62% to USD 20.07 on November 13, with 4.4 mn shares traded.
- Worldwide third-quarter Revenue reached USD 283.7 million, compared with USD 249.3 million a year earlier.
- Gross profit rose to USD 160.4 million from USD 134.3 million, bringing the gross Margin to 57%, versus roughly 54% previously.
- For 2026, management reaffirmed projected sales of approximately USD 1.065 billion to USD 1.085 billion, comprising US sales of USD 730 million to USD 745 million and international sales of USD 335 million to USD 340 million.
Insulin pump shipments, stronger margins and wider access to reimbursement formed a substantial quarterly update for Tandem Diabetes Care Inc. (NASDAQ: TNDM), whose shares advanced 14.62% to USD 20.07 on 13 November 2026. The company’s results for the quarter ended 30 September revealed 14% worldwide sales growth, improved operating performance and ongoing international launches. These figures describe Business activity reported on 5 November; they do not establish that any single announcement caused the subsequent share-price move.
A Larger Global Sales Base
Worldwide third-quarter revenue reached USD 283.7 million, compared with USD 249.3 million a year earlier. US sales totaled USD 191.0 million, up 9%, while international sales rose 26% to USD 92.6 million. Approximately 33,000 pumps were shipped globally, including nearly 23,000 in the United States and nearly 11,000 internationally. Both shipment and revenue figures are relevant because average selling prices and reimbursement arrangements can change the relationship between equipment placements and reported sales.
Margin Gains Accompany Expansion
Gross profit rose to USD 160.4 million from USD 134.3 million, bringing the gross margin to 57%, versus roughly 54% previously. The operating loss narrowed to USD 2.4 million from USD 22.9 million, while the net loss narrowed to USD 7.1 million from USD 21.2 million. Adjusted EBITDA increased to USD 18.0 million from USD 2.8 million. These comparisons show improved profitability measures alongside growing sales, although the company still reported a GAAP net loss.
New Routes to Patients
The company said its pay-as-you-go reimbursement model accounted for 15% of US sales through the pharmacy channel. Pharmacy formulary coverage expanded to approximately half of US covered lives. Tandem also extended t:slim X2 compatibility with the Abbott FreeStyle Libre 3 Plus sensor to 11 international markets and announced Tandem Mobi availability in 12 countries. The developments broaden distribution and device availability, while adoption and eventual revenue depend on patient access and market demand.
Device shipments, channel mix and reimbursement are useful companion measures to reported sales. A rise in pharmacy-channel participation is a distribution change; it should not automatically be treated as a proportional increase in patient numbers. The company’s own results report both GAAP Earnings and adjusted measures, allowing the quarter’s operational progress to be read alongside expenses and net profitability.
Guidance Sets the Year-End Measure
For 2026, management reaffirmed projected sales of approximately USD 1.065 billion to USD 1.085 billion, comprising US sales of USD 730 million to USD 745 million and international sales of USD 335 million to USD 340 million. It also retained expected gross margin of 56% to 57% and adjusted EBITDA margin of 5% to 6%. The targets are expectations rather than completed results. Comparing them with the reported third-quarter sales and margins will provide a clearer view of year-end execution.
For Tandem Diabetes Care Inc., the dates attached to these disclosures are important. The closing price belongs to 13 November 2026, while the operating and financial figures relate to the periods stated by the company. A completed result, a current commitment and a management target each answer a different question. Keeping those distinctions clear allows the next corporate announcement to be compared with previously stated plans without assuming that a market move explains the underlying business performance.
_11_16_2026_11_23_12_237620.jpg)


_11_16_2026_07_52_44_870464.jpg)


Please wait processing your request...